-
EP4220360
European procedure
Extract from the Register of European Patents
EP About this file: EP4220360
| EP4220360 - OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 24.05.2024 Database last updated on 19.10.2024 | |
| Former | Grant of patent is intended Status updated on 22.01.2024 | ||
| Former | Request for examination was made Status updated on 01.09.2023 | ||
| Former | The application has been published Status updated on 30.06.2023 | Most recent event Tooltip | 13.09.2024 | Correction of patent specification | published on 16.10.2024 [2024/42] | Applicant(s) | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2023/31] | Inventor(s) | 01 /
COSTA, Veronica 4058 Basel / CH | 02 /
HEDTJÄRN, Maj 2970 Hørsholm / DK | 03 /
HOENER, Marius 4070 Basel / CH | 04 /
JAGASIA, Ravi 4070 Basel / CH | 05 /
JENSEN, Mads Aaboe 2970 Hørsholm / DK | 06 /
PATSCH, Christoph 69126 Heidelberg / DE | 07 /
PEDERSEN, Lykke 2970 Hørsholm / DK | 08 /
RASMUSSEN, Søren Vestergaard 2970 Hørsholm / DK | [2023/31] | Representative(s) | D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [2024/26] |
| Former [2023/31] | D Young & Co LLP 120 Holborn London EC1N 2DY / GB | Application number, filing date | 23152543.7 | 11.11.2016 | [2023/31] | Priority number, date | EP20150194367 | 12.11.2015 Original published format: EP 15194367 | EP20160189502 | 19.09.2016 Original published format: EP 16189502 | [2023/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP4220360 | Date: | 02.08.2023 | Language: | EN | [2023/31] | Type: | A3 Search report | No.: | EP4220360 | Date: | 23.08.2023 | Language: | EN | [2023/34] | Type: | B1 Patent specification | No.: | EP4220360 | Date: | 26.06.2024 | Language: | EN | [2024/26] | Type: | B9 Corrected patent specification | No.: | EP4220360 | Date: | 16.10.2024 | [2024/42] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 26.07.2023 | Classification | IPC: | C12N15/113 | [2023/34] | CPC: |
G01N33/5014 (EP,IL,US);
A61K31/7088 (CN,IL,KR,RU);
C12N15/1137 (CN,IL,KR,RU,US);
C12N15/111 (CN,IL,RU,US);
A61P25/00 (EP,CN,IL,KR,RU);
A61P25/08 (EP,CN,IL,RU);
A61P25/14 (EP,CN,IL,RU);
A61P25/20 (EP,CN,IL,RU);
A61P25/28 (EP,CN,IL,RU);
C12N15/11 (IL,RU,US);
C12N15/113 (EP,CN,IL,RU,US);
C12N5/0018 (IL,US);
C12N5/0619 (EP,IL,US);
C12N5/0623 (EP,IL,US);
C12N5/0696 (IL,US);
G01N33/5058 (EP,IL,US);
C12N2310/11 (EP,CN,IL,KR,US);
C12N2310/20 (EP,CN,IL,US);
C12N2310/315 (EP,CN,IL,KR,US);
C12N2310/321 (CN,IL,KR,US);
C12N2310/322 (CN,IL,KR,US);
C12N2310/3231 (EP,CN,IL,KR,US);
C12N2310/33 (CN,IL,US);
C12N2310/3341 (EP,CN,IL,US);
C12N2310/341 (EP,CN,IL,KR,US);
C12N2310/346 (EP,CN,IL,US);
C12N2310/351 (CN,IL,KR,US);
C12N2320/34 (EP,IL,KR,US);
C12N2500/38 (EP,IL,US);
C12N2500/44 (EP,IL,US);
C12N2501/01 (EP,IL,US);
C12N2501/11 (EP,IL,US);
C12N2501/115 (EP,IL,US);
C12N2501/119 (EP,IL,US);
C12N2501/13 (EP,IL,US);
C12N2501/41 (EP,IL,US);
C12N2501/60 (EP,IL,US);
C12N2501/727 (EP,IL,US);
C12N2501/999 (EP,IL,US);
|
| Former IPC [2023/31] | G06F3/041, G02B5/30, B32B7/03 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/40] |
| Former [2023/31] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Validation states | MA | 29.08.2023 | Title | German: | OLIGONUKLEOTIDE ZUR INDUKTION DER PATERNALEN UBE3A-EXPRESSION | [2023/31] | English: | OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION | [2023/31] | French: | OLIGONUCLÉOTIDES POUR INDUIRE L'EXPRESSION DE PATERNAL UBE3A | [2023/31] | Examination procedure | 29.08.2023 | Amendment by applicant (claims and/or description) | 29.08.2023 | Examination requested [2023/40] | 29.08.2023 | Date on which the examining division has become responsible | 23.01.2024 | Communication of intention to grant the patent | 17.05.2024 | Fee for grant paid | 17.05.2024 | Fee for publishing/printing paid | 17.05.2024 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP16798440.0 / EP3374509 | EP20204481.4 / EP3798307 | Fees paid | Renewal fee | 05.02.2023 | Renewal fee patent year 03 | 05.02.2023 | Renewal fee patent year 04 | 05.02.2023 | Renewal fee patent year 05 | 05.02.2023 | Renewal fee patent year 06 | 05.02.2023 | Renewal fee patent year 07 | 22.11.2023 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO03000707 (ISIS PHARMACEUTICALS INC [US], et al); | [X]WO2004028458 (PHARMACIA CORP [US], et al); | [X]US2005124572 (FREIER SUSAN M [US], et al); | [IDA]WO2014004572 (ISIS PHARMACEUTICALS INC [US], et al) | by applicant | WO9307883 | WO9839352 | WO9914226 | WO0047599 | WO0066604 | WO0123613 | WO2004046160 | WO2007031091 | WO2007090071 | WO2007134181 | WO2007146511 | WO2008113832 | WO2008150729 | WO2008154401 | WO2009006478 | WO2009067647 | WO2009124238 | WO2010036698 | WO2010077578 | WO2011017521 | WO2011156202 | WO2012064806 | WO2012143379 | WO2013033230 | WO2013036868 | WO2013154798 | WO2014004572 | WO2014076195 | WO2009EP50349 |